Free Trial

Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS

Keros Therapeutics logo with Medical background
Remove Ads

Keros Therapeutics (NASDAQ:KROS - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22, Zacks reports. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.07 during trading on Friday, hitting $11.08. 2,027,042 shares of the company traded hands, compared to its average volume of 1,624,140. The firm has a market capitalization of $448.82 million, a price-to-earnings ratio of -2.13 and a beta of 1.39. The business's fifty day moving average is $12.52 and its 200 day moving average is $39.49. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.

Wall Street Analyst Weigh In

KROS has been the subject of several recent research reports. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and an average target price of $42.33.

Remove Ads

View Our Latest Research Report on Keros Therapeutics

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Further Reading

Earnings History for Keros Therapeutics (NASDAQ:KROS)

Should You Invest $1,000 in Keros Therapeutics Right Now?

Before you consider Keros Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.

While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads